Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct;27(5):519-527.
doi: 10.1017/S2045796017000166. Epub 2017 Jun 5.

Increased cardiovascular mortality in people with schizophrenia: a 24-year national register study

Affiliations

Increased cardiovascular mortality in people with schizophrenia: a 24-year national register study

J Westman et al. Epidemiol Psychiatr Sci. 2018 Oct.

Abstract

AimsPeople who have schizophrenia die earlier from somatic diseases than do people in the general population, but information about cardiovascular deaths in people who have schizophrenia is limited. We analysed mortality in all age groups of people with schizophrenia by specific cardiovascular diseases (CVDs), focusing on five CVD diagnoses: coronary heart disease, acute myocardial infarction, cerebrovascular disease, heart failure and cardiac arrhythmias. We also compared hospital admissions for CVDs in people who had schizophrenia with hospital admissions for CVDs in the general population.

Methods: This national register study of 10 631 817 people in Sweden included 46 911 people who were admitted to the hospital for schizophrenia between 1 January 1987 and 31 December 2010. Information from national registers was used to identify people who had schizophrenia and obtain data about mortality, causes of death, medical diagnoses and hospitalisations.

Results: CVDs were the leading cause of death in people who had schizophrenia (5245 deaths), and CVDs caused more excess deaths than suicide. The mean age of CVD death was 10 years lower for people who had schizophrenia (70.5 years) than the general population (80.7 years). The mortality rate ratio (MRR) for CVDs in all people who had schizophrenia was 2.80 (95% confidence interval (CI) 2.73-2.88). In people aged 15-59 years who had schizophrenia, the MRR for CVDs was 6.16 (95% CI 5.79-6.54). In all people who had schizophrenia, the MRR for coronary heart disease was 2.83 (95% CI 2.73-2.94); acute myocardial infarction, 2.62 (95% CI 2.49-2.75); cerebrovascular disease, 2.4 (95% CI 2.25-2.55); heart failure, 3.25 (95% CI 2.94-3.6); and cardiac arrhythmias, 2.06 (95% CI 1.75-2.43). Hospital admissions for coronary heart disease were less frequent in people who had schizophrenia than in the general population (admission rate ratio, 0.88 (95% CI 0.83-0.94). In all age groups, survival after hospital admission for CVD was lower in people who had schizophrenia than in the general population.

Conclusions: People who had schizophrenia died 10 years earlier from CVDs than did people in the general population. For all five CVD diagnoses, mortality risk was higher for those with schizophrenia than those in the general population. Survival after hospitalisation for CVDs in people who had schizophrenia was comparable with that of people in the general population who were several decades older.

Keywords: Epidemiology; mortality; myocardial infarction; psychosis; schizophrenia; suicide.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Mortality rate ratio (MRR) and age by cause of death in people who had schizophrenia in Sweden between 1990 and 2010. The reference group is the general population of Sweden. The black line represents the MRR, and the grey shading represents the 95% CI.
Fig. 2.
Fig. 2.
Survival after first hospital admission for cardiovascular disease in people who had schizophrenia and people in the general population in Sweden.

References

    1. Barnes TR, Paton C, Cavanagh MR, Hancock E, Taylor DM (2007). A UK audit of screening for the metabolic side effects of antipsychotics in community patients. Schizophrenia Bulletin 33, 1397–1403. - PMC - PubMed
    1. Brown S, Barraclough B, Inskip H (2000). Causes of the excess mortality of schizophrenia. British Journal of Psychiatry 177, 212–217. - PubMed
    1. Buckley PF, Miller DD, Singer B, Arena J, Stirewalt EM (2005). Clinicians’ recognition of the metabolic adverse effects of antipsychotic medications. Schizophrenia Research 79, 281–288. - PubMed
    1. Chugh SS, Jui J, Gunson K, Stecker EC, John BT, Thompson B, Ilias N, Vickers C, Dogra V, Daya M, Kron J, Zheng ZJ, Mensah G, McAnulty J (2004). Current burden of sudden cardiac death: multiple source surveillance versus retrospective death certificate-based review in a large U.S. community. Journal of the American College of Cardiology 44, 1268–1275. - PubMed
    1. Crump C, Winkleby MA, Sundquist K, Sundquist J (2013). Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. American Journal of Psychiatry 170, 324–333. - PubMed

Publication types